JAJohanna M. Anttila

Johanna M. Anttila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johanna M. Anttila has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Juha Klefström

    University of Helsinki

    8 shared publications
  • Pauliina M. Munne

    Cancer Cell Circuitry Laboratory, Translational Cancer Medicine, Medical Faculty, University of Helsinki. P.O. Box 63, Haartmaninkatu 8, FI-00014 Helsinki, Finland

    5 shared publications
  • Johanna Mattson

    Department of Oncology, University of Helsinki & Helsinki University Hospital, Helsinki, Finland

    4 shared publications
  • Andrei Goga

    Department of Cell & Tissue Biology, University of California, San Francisco

    3 shared publications
  • Hanna Ala-Hongisto

    Cancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Program Unit, Faculty of Medicine, University of Helsinki, PO Box 63 (Street address: Haartmaninkatu 8), 00014 University of Helsinki, Helsinki, Finland

    3 shared publications
  • Laura Niinikoski

    Breast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

    3 shared publications

Latest Publications

  • Open Access

    Complex I drives glutamine-dependent TCA cycle to support viability of MYChigh breast cancer cells

    by Johanna M. Anttila, Mariel Savelius, Linda Id, Daniel Nicorici, Juhi Somani, Antti O. Hiltunen, Pauliina M. Munne, Aino Peura, Martina Peltonen, July Aung, et al.


  • Open Access

    Microtubule Inhibition Triggers MYC-Mediated Immunogenic Cell Death in Breast Cancer

    by Ruixian Liu, July Aung, Aino Peura, Antti O Hiltunen, Linda Id, Mariel Savelius, Martina Peltonen, Rita Turpin, Natasha Salmelin, Johanna M Anttila, et al.

    Oncogenic MYC promotes cancer cell proliferation, metabolism, and death, while also driving immunosuppression in the tumour microenvironment, complicating immune-based therapies. To counter MYC-driven immune evasion while leveraging MYC-dependent synthetic lethality (MYC-SL), we identified microtubule-targeting agents, including eribulin, as potent inducers of immunogenic cell death in MYC high triple-negative breast cancer (TNBC). A screen of 528 oncology compounds using damage-associated molecular pattern (DAMP) reporters revealed that microtubule inhibitors induced key DAMPs, including HMGB1 secretion, calreticulin exposure, and double-stranded DNA release, leading to gasdermin-E associated cell death in MYC high TNBCs. Immune cell co-culture assays showed immune activation, and patient-derived explant cultures confirmed pro-inflammatory cytokine responses. In vivo, cell-free media from eribulin-treated MYC high murine TNBCs enhanced tumour protection in vaccination models compared to MYC-knockdown controls, linking MYC-dependent DAMP release to immunogenicity. These findings highlight a dual-function therapeutic strategy: agents that selectively induce MYC-dependent immunogenic cell death can provide both targeted cytotoxicity and local immune stimulation, thereby addressing a key limitation of conventional chemotherapeutics, offering a new approach for MYC-driven cancers.


  • Open Access

    Complex I Drives Glutamine-Dependent TCA Cycle to Support Viability of MYC high Breast Cancer Cells

    by Johanna M. Anttila, Mariel Savelius, Juhi Somani, Daniel Nicorici, Pauliina M. Munne, Linda Id, Aino Peura, Antti O. Hiltunen, July Aung, Ryan Awadhpersad, et al.

    In many cancers, stably elevated MYC levels drive persistent and concerted activation of cell growth promoting anabolic programs and the cell cycle in ways that are distinct from normal cells. Therefore, synthetic-lethal strategies to target MYC reprograming of these pathways may identify new selective anticancer therapies for the treatment of MYC high tumors. Here, we identify enhanced mitochondrial respiration as a hallmark of MYC overexpressing cancer cells. Mitochondrial respiration sustains the TCA cycle by regenerating NAD + through complex I-mediated oxidation of NADH. Metabolic carbon tracing analysis revealed that MYC shifts TCA cycle’s carbon source from glucose to glutamine. Inhibition of the glutamine-fueled TCA cycle using NAD + -depleting complex I inhibitors resulted in MYC-dependent synthetic lethality in breast cancer cells. In mouse models of MYC high tumors, persistent inhibition of tumor growth was achieved through combined inhibition of complex I and glutaminolysis. Our results suggest that the high respiration rate observed in MYC high cells supports glutamine carbon-enriched TCA cycle, rendering MYC high tumors selectively vulnerable to inhibitors of mitochondrial respiration and glutaminolysis.


  • Open Access

    Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

    by Joyce V. Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila, Pauliina M. Munne, Mariel Savelius, Kathleen E. Houlahan, Daniel Van de Mark, et al.


  • Open Access

    Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

    by Joyce V. Lee, Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila, Pauliina M. Munne, Mariel Savelius, Kathleen E. Houlahan, Daniel Van de Mark, et al.

    Few patients with triple negative breast cancer (TNBC) benefit from immune checkpoint inhibitors with complete and durable remissions being quite rare. Oncogenes can regulate tumor immune infiltration, however whether oncogenes dictate diminished response to immunotherapy and whether these effects are reversible remains poorly understood. Here, we report that TNBCs with elevated MYC expression are resistant to immune checkpoint inhibitor therapy. Using mouse models and patient data, we show that MYC signaling is associated with low tumor cell PD-L1, low overall immune cell infiltration, and low tumor cell MHC-I expression. Restoring interferon signaling in the tumor increases MHC-I expression. By combining a TLR9 agonist and an agonistic antibody against OX40 with anti-PD-L1, mice experience tumor regression and are protected from new TNBC tumor outgrowth. Our findings demonstrate that MYC-dependent immune evasion is reversible and druggable, and when strategically targeted, may improve outcomes for patients treated with immune checkpoint inhibitors.


  • Open Access

    Sortilin-related receptor is a druggable therapeutic target in breast cancer

    by Hussein Al-Akhrass, Mika Pietilä, Johanna Lilja, Ella-Maria Vesilahti, Johanna M. Anttila, Heidi M. Haikala, Pauliina M. Munne, Juha Klefström, Emilia Peuhu, Johanna Ivaska

    In breast cancer, the currently approved anti-receptor tyrosine-protein kinase erbB-2 (HER2) therapies do not fully meet the expected clinical goals due to therapy resistance. Identifying alternative HER2-related therapeutic targets could offer means to overcome these resistance mechanisms. We have previously demonstrated that an endosomal sorting protein, sortilin-related receptor (SorLA), regulates the traffic and signaling of HER2 and HER3, thus promoting resistance to HER2-targeted therapy in breast cancer. This study aims to assess the feasibility of targeting SorLA using a monoclonal antibody. Our results demonstrate that anti-SorLA antibody (SorLA ab) alters the resistance of breast cancer cells to HER2 monoclonal antibody trastuzumab in vitro and in ovo . We found that SorLA ab and trastuzumab combination therapy also inhibits tumor cell proliferation and tumor cellularity in a mouse xenograft model of HER2-positive breast cancer. In addition, SorLA ab inhibits the proliferation of breast cancer patient-derived explant three-dimensional cultures. These results provide for the first time proof-of-principle that SorLA is a druggable target in breast cancer.


  • Open Access

    Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy

    by Heidi M. Haikala, Johanna M. Anttila, Elsa Marques, Tiina Raatikainen, Mette Ilander, Henna Hakanen, Hanna Ala-Hongisto, Mariel Savelius, Diego Balboa, Bjoern Von Eyss, et al.

    Elevated MYC expression sensitizes tumor cells to apoptosis but the therapeutic potential of this mechanism remains unclear. We find, in a model of MYC-driven breast cancer, that pharmacological activation of AMPK strongly synergizes with BCL-2/BCL-XL inhibitors to activate apoptosis. We demonstrate the translational potential of an AMPK and BCL-2/BCL-XL co-targeting strategy in ex vivo and in vivo models of MYC-high breast cancer. Metformin combined with navitoclax or venetoclax efficiently inhibited tumor growth, conferred survival benefits and induced tumor infiltration by immune cells. However, withdrawal of the drugs allowed tumor re-growth with presentation of PD-1+/CD8+ T cell infiltrates, suggesting immune escape. A two-step treatment regimen, beginning with neoadjuvant metformin+venetoclax to induce apoptosis and followed by adjuvant metformin+venetoclax+anti-PD-1 treatment to overcome immune escape, led to durable antitumor responses even after drug withdrawal. We demonstrate that pharmacological reactivation of MYC-dependent apoptosis is a powerful antitumor strategy involving both tumor cell depletion and immunosurveillance.


  • Open Access

    MYC and AMPK–Save Energy or Die!

    by Heidi M. Haikala, Johanna M. Anttila, Juha Klefström

    MYC sustains non-stop proliferation by altering metabolic machinery to support growth of cell mass. As part of the metabolic transformation MYC promotes lipid, nucleotide and protein synthesis by hijacking citric acid cycle to serve biosynthetic processes, which simultaneously exhausts ATP production. This leads to the activation of cellular energy sensing protein, AMP-activated protein kinase (AMPK). Cells with normal growth control can stop cell proliferation machinery to replenish ATP reservoirs whereas MYC prevents such break by blocking the cell cycle exit. The relentless cell cycle activation, accompanied by sustained metabolic stress and AMPK activity, switches the energy-saving AMPK to pro-apoptotic AMPK. The AMPK-involving metabolic side of MYC apoptosis may provide novel avenues for therapeutic development. Here we first review the role of anabolic MYC and catabolic AMPK pathways in context of cancer and then discuss how the concomitant activity of both pathways in tumor cells may result in targetable synthetic lethal vulnerabilities.